GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Active Biotech AB (OSTO:ACTI) » Definitions » Debt-to-Equity

Active Biotech AB (OSTO:ACTI) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Active Biotech AB Debt-to-Equity?

Active Biotech AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Active Biotech AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Active Biotech AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr20.10 Mil. Active Biotech AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Active Biotech AB's Debt-to-Equity or its related term are showing as below:

OSTO:ACTI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02   Med: 0.37   Max: 2.71
Current: 0.23

During the past 13 years, the highest Debt-to-Equity Ratio of Active Biotech AB was 2.71. The lowest was 0.02. And the median was 0.37.

OSTO:ACTI's Debt-to-Equity is ranked worse than
59.36% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:ACTI: 0.23

Active Biotech AB Debt-to-Equity Historical Data

The historical data trend for Active Biotech AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Active Biotech AB Debt-to-Equity Chart

Active Biotech AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.09 0.02 0.18 0.15

Active Biotech AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.15 -

Competitive Comparison of Active Biotech AB's Debt-to-Equity

For the Biotechnology subindustry, Active Biotech AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Active Biotech AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's Debt-to-Equity falls into.



Active Biotech AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Active Biotech AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Active Biotech AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Active Biotech AB  (OSTO:ACTI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Active Biotech AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Active Biotech AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Active Biotech AB (OSTO:ACTI) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy.

Active Biotech AB (OSTO:ACTI) Headlines

No Headlines